EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report

Mahshid Mahyad, Mahdieh Baghaei, Ava Baghaei, Mohammadali Nahayati iD

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.70028 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von Mahshid Mahyad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Alopecia, Rituximab, Antibodies, Monoclonal, Humanized, Drug Substitution. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ocrelizumab is a humanized monoclonal antibody, which acts as an anti‐CD20 antibody. It is used as a treatment of both relapsing–remitting multiple sclerosis (RRMS) and Progressive types. The aim of this study is to report the first patient with alopecia universalis after switching from rituximab to ocrelizumab. A 37‐year‐old woman with a history of SPMS, diagnosed 8 years ago, used to be treated with rituximab. Her drug was switched to ocrelizumab from 6 months ago. She presented with patchy scalp hair loss a day after receiving the second dose of ocrelizumab. Her hair loss rapidly progressed in 3–4 days to total body hair loss in a patchy pattern. Ocrelizumab may be responsible for autoimmune reactions such as alopecia universalis in immunocompromised patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlopeciaRituximabAntibodies, Monoclonal, HumanizedDrug SubstitutionHumansFemaleAdultTreatment OutcomeMultiple Sclerosis, Chronic ProgressiveImmunologic FactorsImmunocompromised HostMultiple Sclerosis, Relapsing-Remitting

Stichwörter der Autor:innen

alopecia areataalopecia universalismultiple sclerosisocrelizumabrituximab

Substanzen

RituximabAntibodies, Monoclonal, HumanizedocrelizumabImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Radiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Mohammadali Nahayati

Zitieren

APA

Mahyad, M., Baghaei, M., Baghaei, A., & Nahayati, M. (2024). Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70028

Vancouver

Mahyad M, Baghaei M, Baghaei A, Nahayati M. Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.70028

BibTeX
@article{Mahyad2024,
  author = {Mahyad, Mahshid and Baghaei, Mahdieh and Baghaei, Ava and Nahayati, Mohammadali},
  title = {Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.70028}
}
Kostenlos starten →